Prophylactic effect of Malarone against malaria: All good news?

Lancet

Volumn 356, Issue 9245, 2000, Pages 1864-1865

  Nosten, François ^a,b,c  

^a SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; PROGUANIL;

CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG COST; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; KENYA; MALARIA; MALARIA CONTROL; NOTE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; TRAVEL;

EID: 0034597891     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)03250-5     Document Type: Note

References (13)

1. New drug offers alternative treatment for PCP
2. Atovaquone and proguanil for Plasmodium falciparum malaria
3. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malana in Zambia
4. Doctors revise declaration of Helsinki
5. Examination of some factors responsible for a food-induced increase in absorption of atovaquone
6. The mosquito transmission of malaria the effects of atovaquoneproguanil (Malarone) and chloroquine
7. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4- (4'-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80)
8. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site
9. Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites
10. A mechanism for the synergistic antimalarial action of atovaquone and proguanil
11. Delaying antimalarial drug resistance with combination chemotherapy
12. Sustainability, affordability, and equity of corporate drug donations the case of Malarone
13. Malarone-donation programme in Africa